Healthcare - Biotechnology - NASDAQ - US
$ 0.85
-0.117 %
$ 51.3 M
Market Cap
-0.49
P/E
CASH FLOW STATEMENT
-78.6 M
OPERATING CASH FLOW
66.4 M
INVESTING CASH FLOW
567 K
FINANCING CASH FLOW
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Kronos Bio, Inc.
| Net Income | -113 M |
| Depreciation & Amortization | 2.14 M |
| Capital Expenditures | -679 K |
| Stock-Based Compensation | 25 M |
| Change in Working Capital | 5.88 M |
| Others | 11.1 M |
| Free Cash Flow | -79.3 M |
Cash Flow
Millions
| Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | Dec-2018 | |
|---|---|---|---|---|---|---|
| OPERATING CASH FLOW | ||||||
| Net Income | (112.7) | (133.2) | (151.1) | (88.4) | (16.1) | (6.7) |
| Depreciation & Amortization | 2.1 | 2.3 | 2.0 | 0.8 | 0.4 | 91 K |
| Deferred Income Tax | 0 | 0 | 4.0 | 0.3 | 4 K | 0 |
| Stock Based Compensation | 25.0 | 31.1 | 26.2 | 3.8 | 0.1 | 30 K |
| Other Operating Activities | 1.1 | 2.7 | 2.6 | 39.2 | 0.3 | 69 K |
| Change in Working Capital | 5.9 | 6.2 | (1.6) | 6.5 | 0.3 | 90 K |
| Cash From Operations | (78.6) | (90.9) | (117.9) | (37.9) | (15.1) | (6.4) |
| INVESTING CASH FLOW | ||||||
| Capital Expenditures | (0.7) | (0.6) | (4.3) | (9.6) | (2.9) | (1.1) |
| Other Items | 67.0 | (31.6) | 68.0 | (150.7) | (64.6) | 0 |
| Cash From Investing Activities | 66.4 | (32.2) | 63.7 | (160.2) | (67.6) | (1.1) |
| FINANCING CASH FLOW | ||||||
| Common Stock Repurchased | 0.5 | 0.4 | 1.3 | 0 | 0 | 0 |
| Total Debt Repaid | 0 | 0 | 5 K | 151.2 | 30 K | 72 K |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0.6 | 0.9 | 4.5 | 264.4 | 105.0 | 16.3 |
| Cash From Financing Activities | 0.6 | 0.9 | 4.5 | 415.6 | 105.0 | 16.2 |
| CHANGE IN CASH | ||||||
| Net Change In Cash | (11.6) | (122.3) | (49.7) | 217.5 | 22.3 | 8.7 |
| FREE CASH FLOW | ||||||
| Free Cash Flow | (79.3) | (91.5) | (122.2) | (47.5) | (18.0) | (7.5) |